Literature DB >> 6336658

Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells.

P G Natali, P Giacomini, A Bigotti, K Imai, M R Nicotra, A K Ng, S Ferrone.   

Abstract

Surgically removed normal and malignant mammary tissues and human breast carcinoma cell lines were tested in binding assays with monoclonal antibodies to HLA-A,B,C antigens, beta 2-microglobulin, HLA-DR antigens, and tumor-associated antigens; the latter included a Mr 280,000, a Mr 94,000, and a Mr 85,000 membrane-bound glycoprotein and a cytoplasmic antigen. HLA-A,B antigens, beta 2-microglobulin, HLA-DR antigens, and the cytoplasmic antigen are expressed by normal mammary cells. Their malignant transformation may be associated with quantitative changes in the expression of these antigens and with the appearance of Mr 94,000 and Mr 85,000 glycoproteins. The Mr 280,000 glycoprotein was detected on only one of the breast carcinoma cell lines tested. Analysis of primary tumors and autologous axillary lymph node metastasis from 13 patients has shown differences in the expression of all the antigens tested between primary and metastatic lesions.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6336658

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  Inhibition of HLA class I antigen and mRNA expression induced by Rous sarcoma virus in transformed human fibroblasts.

Authors:  J Gogusev; B Teutsch; M T Morin; F Mongiat; F Haguenau; G Suskind; G F Rabotti
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

2.  HLA-DR and beta 2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities.

Authors:  M Feinmesser; A Sulkes; S Morgenstern; J Sulkes; S Stern; E Okon
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

Review 3.  Autologous graft-versus-host disease.

Authors:  M J Kennedy; A D Hess
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

4.  A transcription factor interacting with the class I gene enhancer is inactive in tumorigenic cell lines which suppress major histocompatibility complex class I genes.

Authors:  U Henseling; W Schmidt; H R Schöler; P Gruss; A K Hatzopoulos
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

5.  Localization of a membrane glycoprotein in benign fibrocystic disease and infiltrating duct carcinomas of the human breast with the use of a monoclonal antibody to guinea pig milk fat globule membrane.

Authors:  D E Greenwalt; V G Johnson; F P Kuhajda; J C Eggleston; I H Mather
Journal:  Am J Pathol       Date:  1985-03       Impact factor: 4.307

6.  HLA-DR expression is associated with excellent prognosis in squamous cell carcinoma of the larynx.

Authors:  F Esteban; F Ruiz-Cabello; A Concha; M Pérez-Ayala; J A Sánchez-Rozas; F Garrido
Journal:  Clin Exp Metastasis       Date:  1990 Jul-Aug       Impact factor: 5.150

7.  Presence of HLA-D/DR antigens on the membrane of breast tumour cells.

Authors:  D Bernard; J C Maurizis; F Rusé; J Chassagne; P Chollet; B Sauvezie; M de Latour; R Plagne
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

8.  Autocrine induction of major histocompatibility complex class I antigen expression results from induction of beta interferon in oncogene-transformed BALB/c-3T3 cells.

Authors:  M K Offermann; D V Faller
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

Review 9.  Autologous graft-versus-host disease: immunotherapy of breast cancer after bone marrow transplantation.

Authors:  M J Kennedy; R J Jones
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

10.  Distribution of S-100 protein-positive dendritic cells and expression of HLA-DR antigen in transitional cell carcinoma of the urinary bladder in relation to tumour progression and prognosis.

Authors:  K Inoue; M Furihata; Y Ohtsuki; Y Fujita
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.